Michael Nevradakis is an editor and writer whose work focuses on a variety of topics. He has written for publications such as Children's Health Defense, GlobalResearch, LifeSiteNews, and The Epoch Times. His articles cover issues related to health, politics, and global events, often challenging mainstream narratives and offering alternative perspectives.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Michael Nevradakis covers a wide range of topics, with a focus on healthcare and pharmaceuticals, government and politics, culture and society. He appears to prioritize articles that include government announcements, legal policy regulations, data citations or expert commentary.
Given his coverage attributes and themes covered, Michael is likely to respond well to pitches from experts in the fields of public health policy or regulatory affairs. Pitches should provide insights into government policies related to healthcare and pharmaceuticals or offer new data analysis relevant to these areas.
It's also important for sources reaching out to Michael to have expertise in addressing societal issues impacted by governmental decisions as they relate to healthcare. This could involve providing unique perspectives on cultural implications of medical developments such as vaccines or surveillance technologies.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Michael Nevradakis
The Center for Countering Digital Hate, authors of “The Disinformation Dozen,” faces a Nov. 21 deadline to provide Congress with documents related to its alleged collusion with the Biden administration and social media platforms to censor online users.
By: Michael Nevradakis
Highlights from last week's congressional hearing on lessons learned from the COVID-19 pandemic included criticism of government-mandated lockdowns and masks, and public health agencies' lack of oversight and proper safety testing of the COVID-19 vaccines.
By: Michael Nevradakis
In a letter to Facebook, Google, Microsoft and Apple, Brendan Carr warned the companies they may lose the protections they enjoy under Section 230 of the Communications Decency Act of 1996, described as “Big Tech's prized liability shield.”
By: Michael Nevradakis
Focusing on stories of overcoming pandemic-era government overreach, censorship, vaccine injury and the suppression of alternative treatments for COVID-19, the newly published “Canary in a (Post) Covid World: Money, Fear and Power” features chapters from 37 contemporary thought leaders.
By: Michael Nevradakis
Four monkeys remain at large after 43 escaped earlier this month from the Alpha Genesis Primate Research Center in South Carolina. The lab, which has received over $109 million in federal funding, helped develop several therapeutic drugs and vaccines, including those to treat COVID-19.
By: Michael Nevradakis
Sayer Ji, founder of GreenMedInfo and one of “The Disinformation Dozen” joined “The Defender In-Depth” this week to discuss revelations about the Center for Countering Digital Hate and what lies ahead now that the group's plans may have been derailed.
By: Michael Nevradakis
The request stems from a lawsuit filed in March alleging the Washington Medical Commission violated doctors' First Amendment right to criticize the “mainstream COVID narrative” and the public's First Amendment right to hear the opposing viewpoints.
By: Michael Nevradakis
President-elect Donald Trump's nominees to lead three key federal public health agencies “would help the incoming president shift the priorities of agencies that are linchpins in public health” — but they're also “controversial,” according to NPR.
By: Michael Nevradakis
A new book by Children's Health Defense, “The Medical-Pharmaceutical Killing Machine: Facing Facts Could Save Your Life,” documents “systemized medical abuse” that accelerated during the COVID-19 pandemic. The book, released today, was the subject of a CHD.TV roundtable discussion last week.
By: Michael Nevradakis
U.S. Senate Finance Committee members who will vote first on Robert F. Kennedy Jr.'s nomination for HHS secretary individually have accepted “hundreds of thousands of dollars in contributions from the pharmaceutical industry,” The Federalist reported.
(833) 317-6278 
